Swiss obesity start up SixPeaks Bio AG has made a good start, announcing a US$30m Series A financing led by Versant Ventures and a US$80m biobucks partnership with AstraZeneca plc.
Sino Biological offers a comprehensive array of recombinant cytokines tailored for cell culture to advance research in tumor immunotherapy, stem cell therapy, drug screening, and regenerative medicine.
Obesity candidate CT-388, which Genentech added to Roche’s pipeline with the acquisition of Carmot Therapeutics, is at least not a disappointment, according to new trial data.
https://european-biotechnology.com/wp-content/uploads/2024/06/Roche3.png9101608Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2024-05-19 12:02:002024-07-08 11:14:34Obesity: Roche with first clinical data after US$2.7bn deal
British PrecisionLife Ltd and the Metrodora Institute have announced to launch clinical trials to improve the diagnosis and therapy of long COVID-related ME/CFS.
https://european-biotechnology.com/wp-content/uploads/2024/07/EB.com_John_E_Milad_kl.jpg773688Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2024-05-15 11:17:002024-07-16 16:56:29ERS Genomics with new CEO
https://european-biotechnology.com/wp-content/uploads/2024/06/Molecular_Devices.png399450/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png2024-05-15 07:25:002024-05-15 07:25:00Transform Your Clonal Selection with Quantitative Fluorescent Screening
German-Portuguese biotech start-up MicroHarvest GmbH and a Munich-based pet food manufacturer want to launch the first dog snack made by single cell protein.
https://european-biotechnology.com/wp-content/uploads/2024/06/puppy-1207816_1280.jpeg9241280Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2024-05-14 12:38:002024-07-09 12:17:57First dog snack from microbial protein
AC Immune and Takeda have inked an exclusive option license agreement for ACI-24.060, a first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression.
AstraZeneca puts step into obesity market
Latest NewsSwiss obesity start up SixPeaks Bio AG has made a good start, announcing a US$30m Series A financing led by Versant Ventures and a US$80m biobucks partnership with AstraZeneca plc.
Best-In-Class Cytokines
ProductsSino Biological offers a comprehensive array of recombinant cytokines tailored for cell culture to advance research in tumor immunotherapy, stem cell therapy, drug screening, and regenerative medicine.
LabGenius raises £35m to expand its antibody discovery platform
Latest NewsLondon-based AI-driven antibody drug discovery specialist LabGenius Ltd has closed a £35m Series B financing round.
Seed financing for Cellugy A/S
Latest NewsDanish industrial biotechnology startup Cellugy raises €4,9m with the ambition to replace petrochemicals in personal care products.
Obesity: Roche with first clinical data after US$2.7bn deal
Latest NewsObesity candidate CT-388, which Genentech added to Roche’s pipeline with the acquisition of Carmot Therapeutics, is at least not a disappointment, according to new trial data.
British PrecisionLife Ltd inks partnership with Metrodora Institute
Latest NewsBritish PrecisionLife Ltd and the Metrodora Institute have announced to launch clinical trials to improve the diagnosis and therapy of long COVID-related ME/CFS.
ERS Genomics with new CEO
AppointmentsDublin-based ERS Genomics Ltd appointed John E Milad as CEO in the middle of May. He took over from Erik Rhodes, CEO for the last eight years.
Transform Your Clonal Selection with Quantitative Fluorescent Screening
ProductsInnovate in Bio-Production – Discover how Fermentalg® is revolutionizing the natural food ingredient industry using the power of microalgae.
First dog snack from microbial protein
Latest NewsGerman-Portuguese biotech start-up MicroHarvest GmbH and a Munich-based pet food manufacturer want to launch the first dog snack made by single cell protein.
AC Immune and Takeda ink US$2.1bn biobucks deal
Latest NewsAC Immune and Takeda have inked an exclusive option license agreement for ACI-24.060, a first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression.